Sign inJoin waitlistJoin the waitlist

KL

Kian-Huat Lim

Physician · Washington University School of Medicine

Credentials: · · · · ·

History

Washington University School of Medicine
Present

National Institutes of Health
2001–2002
Internal Medicine
Barnes-Jewish Hospital
1998–2001
National Institutes of Health
1994–1998

Research

Oncogenically active MYD88 mutations in human lymphoma
Nature · 2011 · 1,236 citations
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a…
The Lancet Oncology · 2016 · 679 citations
Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point
Cell Reports · 2015 · 401 citations

Andrea Wang-Gillam
25 papers
PG
Patrick Grierson
17 papers · 10 as a fellow
Ryan Fields
16 papers
BT
Benjamin Tan
14 papers
Marianna Ruzinova
14 papers
William Hawkins
13 papers
KP
Katrina Pedersen
10 papers
RS
Rama Suresh
10 papers
Craig Lockhart
9 papers
Manik Amin
7 papers
HJ
Hong Jiang
6 papers
HP
Haeseong Park
5 papers

Grants

Targeting Tumor Innate Immune Signaling in Pancreatic Cancer
National Cancer Institute · R01
Contact PI · $789.8K · Washington University
2018–2030
Washington University PDX Development and Trial Center
National Cancer Institute · U54
Project lead · $849.9K · Washington University
2017–2028
Washington University SPORE in Pancreatic Cancer
National Cancer Institute · P50
PI · $6.8M · Washington University
2023–2028
Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer
National Cancer Institute · R01
Contact PI · $2.4M · Washington University
2023–2028

Clinical trials

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Principal investigator · Completed · Phase 1
Washington University School of Medicine
2021–2022
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Principal investigator · Completed · Phase 1
Washington University School of Medicine
2019–2022
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Principal investigator · Completed · Phase 1, Phase 2
Washington University School of Medicine
2018–2024
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Principal investigator · Completed · Phase 2
Washington University School of Medicine
2017–2023